LAYER Kalimantan New

4Doctor Layer KALAU ADA PERUBAHAN DI FORM LAYER (SILAHKAN REFRESH SHEET "PivotLayer"-->pada sheet berwarna hijau)

5Doctor Project 2010

Group NO Area NAMA PSR C1-10 C2-10 C3-10### 1 Kalimantan Vacant (eks Haspi)### 2 Kalimantan Vacant (eks Haspi)### 3 Kalimantan Vacant (eks Haspi) 1 1 1### 4 Kalimantan Vacant (eks Haspi)### 5 Kalimantan Vacant (eks Haspi)### 6 Kalimantan Vacant (eks Haspi)### 7 Kalimantan Vacant (eks Haspi)### 8 Kalimantan Vacant (eks Haspi) 1 1 1### 9 Kalimantan Vacant (eks Haspi) 1### 10 Kalimantan Vacant (eks Haspi) 1### 11 Kalimantan Vacant (eks Haspi)### 12 Kalimantan Vacant (eks Haspi) 1 1 1### 13 Kalimantan Vacant (eks Haspi)### 14 Kalimantan Vacant (eks Haspi)### 15 Kalimantan Vacant (eks Haspi) 1 1### 19 Kalimantan Vacant (eks Haspi) 1 1 1### 20 Kalimantan Vacant (eks Haspi) 1 1 1### 21 Kalimantan Vacant (eks Haspi) 1 1 1### 22 Kalimantan Vacant (eks Haspi) 1 1 1### 23 Kalimantan Vacant (eks Haspi) 1 1 1### 25 Kalimantan Vacant (eks Haspi)### 26 Kalimantan Vacant (eks Haspi)### 27 Kalimantan Vacant (eks Haspi)### 28 Kalimantan Vacant (eks Haspi)### 29 Kalimantan Vacant (eks Haspi)### 30 Kalimantan Vacant (eks Haspi)### 31 Kalimantan Vacant (eks Haspi)### 32 Kalimantan Fajar Yuliani

Kalimantan Fajar Yuliani 1 1 1Kalimantan Fajar Yuliani

### 34 Kalimantan Fajar Yuliani### 35 Kalimantan Fajar Yuliani 1 1 1### 36 Kalimantan Fajar Yuliani### 37 Kalimantan Fajar Yuliani 1 1 1### 38 Kalimantan Fajar Yuliani 1 1 1### 39 Kalimantan Fajar Yuliani### 40 Kalimantan Fajar Yuliani### 41 Kalimantan Fajar Yuliani### 42 Kalimantan Fajar Yuliani### 43 Kalimantan Fajar Yuliani 1 1 1### 44 Kalimantan Fajar Yuliani 1 1 1

Margareta 1 1 1

Result AnalysisResult Analysis How to Close the GapHow to Close the Gap

LAYERLAYER

Effectiveness Analysis (IDP)


Margareta 1 1 1MargaretaMargareta

### 45 Kalimantan Vacant (eks Fina)### 47 Kalimantan Vacant (eks Fina) 1 1 1### 49 Kalimantan Vacant (eks Fina) 1 1### 50 Kalimantan Vacant (eks Fina)### 51 Kalimantan Vacant (eks Fina)### 52 Kalimantan Vacant (eks Fina) 1 1 1### 53 Kalimantan Vacant (eks Fina) 1 1 1### 54 Kalimantan Vacant (eks Fina) 1 1 1### 56 Kalimantan Vacant (eks Fina) 1 1 1### 57 Kalimantan Vacant (eks Fina) 1### 58 Kalimantan Vacant (eks Fina)### 60 Kalimantan Vacant (eks Fina)### 61 Kalimantan Vacant (eks Fina) 1 1 1### 62 Kalimantan Vacant (eks Fina)### 63 Kalimantan Vacant (eks Fina)### 64 Kalimantan Vacant (eks Fina) 1 1 1### 65 Kalimantan Vacant (eks Fina) 1 1 1### 66 Kalimantan Vacant (eks Fina)### 67 Kalimantan Vacant (eks Bhakti) 1 1 1### 68 Kalimantan Vacant (eks Bhakti) 1 1 1

Kalimantan Vacant (eks Bhakti) 1 1 1### 69 Kalimantan Vacant (eks Bhakti) 1 1 1### 70 Kalimantan Vacant (eks Bhakti) 1 1 1### 71 Kalimantan Vacant (eks Bhakti) 1 1 1### 72 Kalimantan Vacant (eks Bhakti) 1 1 1### 73 Kalimantan Vacant (eks Bhakti) 1 1 1### 74 Kalimantan Vacant (eks Bhakti) 1 1 1### 75 Kalimantan Vacant (eks Bhakti) ### 76 Kalimantan Vacant (eks Bhakti) ### 77 Kalimantan Vacant (eks Bhakti) ### 78 Kalimantan Vacant (eks Bhakti) ### 79 Kalimantan Vacant (eks Bhakti) ### 80 Kalimantan Vacant (eks Bhakti) 1 1 1### 81 Kalimantan Vacant (eks Bhakti) ### 82 Kalimantan Vacant (eks Bhakti) ### 83 Kalimantan Vacant (eks Bhakti) 1 1 1### 84 Kalimantan Vacant (eks Bhakti) ### 85 Kalimantan Vacant (eks Bhakti) ### 86 Kalimantan Vacant (eks Bhakti) ### 87 Kalimantan Vacant (eks Bhakti) ### 88 Kalimantan Vacant (eks Bhakti) 1 1 1### 89 Kalimantan Vacant (eks Bhakti) 1 1 1### 91 Kalimantan Vacant (eks Bhakti) 1 1 1### 92 Kalimantan Vacant (eks Bhakti) ### 93 Kalimantan Vacant (eks Bhakti) ### 94 Kalimantan Vacant (eks Bhakti) ### 95 Kalimantan Vacant (eks Bhakti)

### 96 Kalimantan Vacant (eks Bhakti) ### 97 Kalimantan Vacant (eks Bhakti)

KALAU ADA PERUBAHAN DI FORM LAYER (SILAHKAN REFRESH SHEET "PivotLayer"-->pada sheet berwarna hijau)

NAMA DOKTER VSN LAYER JML PASIEN

Lianda Siregar, SpPD Ultracet 1 15 28 24Kuntjoro Yakti, SpPD Ultracet 1 20 28 24Fritz Nahusuli, SpB Ultracet 1 13 15 20Ishaq Hardiansyah, SpBU Ultracet 1 15 15 20Arie Ibrahim, SpBS Ultracet 1 10 28 24Eliawati Hadibrata, SpS Ultracet 1 30 28 20Maruf, SpBS Ultracet 1 10 15 20David H Masjhoer, SpOT Ultracet 1 25 15 20Benida, SpAn Durogesic 2 10 1 20Benida, SpAn Fentanyl 1 10 1 20Abdul Haris, SpAn Fentanyl 3 5 1 20L Tandi Susanto Ultracet 1 35 20 24Maria Gabriela Ultracet 3 20 10 24Mangalindung, SpB Ultracet 1 10 10 24Gregorius Tekwan, SpOT Ultracet 1 15 15 24Rudi Peleh, SpAn Fentanyl 1 20 2 24Satria, SpAn Durogesic 1 30 1 24Dwiana Sulistyanti, SpAn Fentanyl 1 15 1 24Ramelan Adiputra Nur, SpB Ultracet 1 15 15 24Satria, SpAn Fentanyl 1 30 1 24Issaq Hardiansyah, SpBU Durogesic 1 5 1 24Swandi Bustani Ultracet 2 20 10 24Andi Majid, SpPD Ultracet 1 10 20 24Fernata bangun, SpAn Fentanyl 2 10 1 24Sopianita tavip Ultracet 2 10 10 24Boyke, SpU Durogesic 2 8 1 20Boyke, SpU Ultracet 1 8 30 20Eliawati Hadibrata, SpS Doribax 1 30 15 24Kuntjoro Yakti, SpPD Eprex 1 15 8 24Satria,SpAn Doribax 1 10 15 24Enny Pasolang, SpPD Doribax 1 15 15 15Dyah Sawitri, SpPD Eprex 2 15 4 24Andi Majid Doribax 1 5 15 25Lianda Siregar, SpPD Doribax 1 10 15 24Tri Prabowo, SpPD Eprex 1 20 8 20AZ Ma'ruf Doribax 1 10 15 20Donni Doribax 1 5 15 24Aswad Muhammad Doribax 1 10 15 24Arie Ibrahim, SpBS Doribax 1 10 15 24Carta A Gunawan, SpPD Doribax 1 20 15 24Effendy Pardede, SpPD Eprex 1 10 4 24Edi Iskandar Dr.,SpPD Eprex 1 20 1 20

JML TAB/R

HARI KERJA


Effectiveness Analysis (IDP) Action PlanAction Plan RRSRRS Execution&MonitoringExecution&Monitoring Outlet MonitoringOutlet Monitoring

Lukman Hatta Dr.,SpPD Eprex 1 25 1 20Nono Maturangan Dr.,SpPD Eprex 1 25 1 20Nani Prasedjo Dr.,SpPD Eprex 1 20 1 20Adi Aryanto, SpOT Ultracet 1 8 15 20Agus Tri Budi W, SpAN Fentanyl 1 15 1 24Alexander, SpOT Ultracet 1 10 15 20Doddy Priambodo, SpBS Ultracet 1 10 15 20Edi Iskandar, SpPD Ultracet 1 25 20 24Hendra Gunawan, SpS Ultracet 1 30 20 24Hendra Gunawan, SpS Topamax25 1 30 14 24Hendra Gunawan, SpS Topamax50 1 30 14 24HM Darwis Dahlan, SpB Ultracet 1 10 15 20Indra Peni, SpOT Ultracet 1 20 15 20Jaya Mualimin, SpKJ haldec 1 10 1 20Lukman Hatta, SpPD Ultracet 1 25 20 24M. Yunus, SpAN Fentanyl 1 15 1 24Nani Prasedjo, SpPD Ultracet 1 10 20 20Nono Maturangan, SpPD Ultracet 1 15 20 20Prasetiawan, SpBU Ultracet 1 15 15 20Sarmauli Sitorus, SpS Ultracet 1 20 20 24

Sentot, SpBO Fentanyl 1 15 1 24

Santosa Tanuseputra Ultracet 1 30 15 24Izaak Zoelkarnain Akbar, SpOT, FICS Ultracet 1 25 20 24Zairin Noor Helmi,SpOT, K.SPINE Ultracet 1 25 15 24Andreas Siagiaan,SpOT Ultracet 1 20 15 24David Tanaputra Ultracet 1 20 15 24Dedy Rasyidan Yulizar,SpU Ultracet 1 20 15 24Agus Yuwono,SpPD Ultracet 1 30 20 24Agus Yuwono,SpPD Durogesic25 3 30 1 24I Gde Sudaadnyana,SpPD Ultracet 1 25 20 24Budianto,SpBOnk Ultracet 1 12 15 20Budianto,SpBOnk Durogesic12,5 2 12 1 20Budianto,SpBOnk Durogesic25 2 12 1 20Djohan Sebastian,SpPD Ultracet 1 20 20 24Djohan Sebastian,SpPD Durogesic12,5 3 20 1 24Darwin Prenggono,SpPD Durogesic25 1 20 1 24Tjahyo Kelono Utomo,SpB Durogesic25 2 15 1 20Wiwit Agung SNC,SpPD Ultracet 1 10 20 24Basuki Rachmad,SpAn Fentanyl2ml 2 6 1 24Kararawji,SpAn Fentanyl2ml 1 8 1 24Herudento,SpPD Ultracet 1 12 20 24Herudento,SpPD Durogesic25 1 12 1 24Binsar Parhusip,SpB Durogesic25 1 15 1 24Zainuddin Arpandy,Sp.S Topamax25 1 50 14 24Zainuddin Arpandy,Sp.S Topamax50 1 50 7 24Zainuddin Arpandy,Sp.S Topamax100 1 50 7 24Aris Geson,SpS Topamax100 1 10 7 24Oscar Nurhadi,SpS Topamax50 2 30 7 24Oscar Nurhadi,SpS Topamax25 1 30 14 24Yulizar Darwis,SpKJ Haldec - 10 1 24

Herawaty Haldec - 10 1 20Retna Utami,SpAn Fentanyl2ml 1 8 1 24

3,194,093,975 878POTENSI DR ASUMSI CURRENT SALES

HNA ASUMSI UNIT (a) VALUE (a) UNIT(s)

30 166,950 5.0 4.0 112.0 18,698,400 4 30 166,950 6.0 5.0 134.4 22,438,080 3 30 166,950 11.0 9.0 110.0 18,364,500 8 30 166,950 15.0 8.0 150.0 25,042,500 2 30 166,950 3.0 2.0 67.2 11,219,040 6 30 166,950 5.0 2.0 93.3 15,582,000 2 30 166,950 15.0 6.0 150.0 25,042,500 5 30 166,950 15.0 18.0 150.0 25,042,500 10 5 600,000 5.0 2.0 20.0 12,000,0005 140,000 10.0 10.0 40.0 5,600,0005 140,000 5.0 5.0 20.0 2,800,000

30 166,950 10.0 13.0 160.0 26,712,000 20 30 166,950 Menengah 2.0 2.0 16.0 2,671,200 5 30 166,950 Menengah 5.0 5.0 40.0 6,678,000 2 30 166,950 Menengah 10.0 12.0 120.0 20,034,000 3 5 140,000 15.0 18.0 144.0 20,160,0005 600,000 Menengah 10.0 9.0 48.0 28,800,0005 140,000 Menengah 10.0 10.0 48.0 6,720,000

30 166,950 Menengah 10.0 8.0 120.0 20,034,000 15 5 140,000 Menengah 15.0 20.0 72.0 10,080,0005 600,000 5.0 2.0 24.0 14,400,000

30 166,950 Menengah 4.0 3.0 32.0 5,342,400 3 30 166,950 Menengah 6.0 3.0 96.0 16,027,200 9 5 140,000 Menengah 10.0 6.0 48.0 6,720,000

30 166,950 Menengah 6.0 3.0 48.0 8,013,600 3 5 600,000 Menengah 5.0 2.0 20.0 12,000,000

30 166,950 Menengah 5.0 3.0 100.0 16,695,000 3 1 440,000 1.0 0.1 360.0 158,400,0006 505,000 5.0 3.0 160.0 80,800,000 55 1 440,000 1.0 0.1 360.0 158,400,0001 440,000 1.0 0.2 3.5 1,540,0006 255,000 2.0 1.0 32.0 8,160,000 4 1 440,000 1.0 0.1 375.0 165,000,0001 440,000 2.0 0.2 720.0 316,800,0006 505,000 10.0 8.0 266.7 134,666,667 60 1 440,000 1.0 0.1 300.0 132,000,0001 440,000 1.0 0.1 360.0 158,400,0001 440,000 1.0 0.1 360.0 158,400,0001 440,000 1.0 0.1 360.0 158,400,0001 440,000 2.0 0.2 720.0 316,800,000 3 6 505,000 2.0 1.5 32.0 16,160,000 1 1 505,000 8.0 3.0 160.0 80,800,000 150

NO of CASE per DAY

JML TAB/BOX

CLASS PASIEN

CONFIRMMenengah

keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatas

Menengah keatas

Menengah Keatas

Menengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatas

1 505,000 12.0 8.0 240.0 121,200,000 60 1 505,000 5.0 2.0 100.0 50,500,0001 505,000 3.0 1.0 60.0 30,300,000

30 166,950 7.0 5.0 70.0 11,686,500 15 1 28,000 Menengah 15.0 15.0 360.0 10,080,000 50

30 166,950 Menengah 8.0 7.0 66.7 11,130,000 3 30 166,950 5.0 4.0 40.0 6,678,000 15 30 166,950 5.0 4.0 66.7 11,130,000 5 30 166,950 Menengah 10.0 8.0 50.0 8,347,500 50 60 258,000 Menengah 10.0 10.0 106.7 17,808,000 7 60 395,000 Menengah 10.0 10.0 40.0 24,000,000 17 30 166,950 5.0 5.0 50.0 8,347,500 4 30 166,950 15.0 15.0 160.0 26,712,0001 117,370 10.0 7.0 213.3 25,038,933 1

30 166,950 5.0 5.0 53.3 8,904,000 4 1 28,000 Menengah 15.0 15.0 66.7 1,866,667 50

30 166,950 4.0 3.0 80.0 13,356,000 3 30 166,950 3.0 4.0 22.4 3,739,680 3 30 166,950 9.0 8.0 120.0 20,034,000 6 30 166,950 10.0 7.0 50.0 8,347,500 14

1 28,000 Menengah 15.0 15.0 9.6 268,800

30 166,950 15.0 15.0 16.0 9,600,000 14 30 166,950 15.0 20.0 12.0 7,200,000 33 30 166,950 15.0 20.0 20.0 12,000,000 8 30 166,950 15.0 15.0 180.0 30,051,000 7 30 166,950 3.0 3.0 36.0 6,010,200 10 30 166,950 15.0 15.0 180.0 30,051,000 18 30 166,950 10.0 15.0 160.0 26,712,000 8 5 600,000 1.0 1.0 4.8 2,880,000

30 166,950 Menengah 10.0 10.0 160.0 26,712,000 20 30 166,950 5.0 8.0 50.0 8,347,500 5 5 375,000 2.0 2.0 8.0 3,000,000 5 5 600,000 2.0 2.0 8.0 4,800,000

30 166,950 Menengah 7.0 5.0 112.0 18,698,400 4 5 375,000 Menengah 1.0 1.0 4.8 1,800,000 3 5 600,000 5.0 3.0 24.0 14,400,000 1 5 600,000 2.0 2.0 8.0 4,800,000 1

30 166,950 Menengah 6.0 5.0 96.0 16,027,200 3 5 140,000 Menengah 6.0 6.0 28.8 4,032,000 5 5 140,000 Menengah 8.0 8.0 38.4 5,376,000 10

30 166,950 8.0 5.0 128.0 21,369,600 3 5 600,000 2.0 2.0 9.6 5,760,0005 600,000 Menengah 3.0 2.0 14.4 8,640,000 1

60 258,000 7.0 5.0 39.2 10,113,600 3 60 395,000 7.0 5.0 19.6 7,742,000 8 60 612,000 7.0 5.0 19.6 11,995,200 3 60 612,000 Menengah 5.0 3.0 14.0 8,568,000 2 60 395,000 Menengah 5.0 4.0 14.0 5,530,000 6 60 258,000 Menengah 5.0 4.0 28.0 7,224,000 2 5 117,370 Menengah 3.0 2.0 14.4 1,690,128 5

Menengah keatasMenengah keatasMenengah keatasMenengah keatas

Menengah keatasMenengah keatas



Menengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatasMenengah keatas

Menengah keatasMenengah keatasMenengah keatas

Menengah keatasMenengah keatas

Menengah kebawahMenengah kebawah

Menengah keatasMenengah keatasMenengah keatas

5 117,370 Menengah 1.0 1.0 4.0 469,480 4 5 140,000 Menengah 8.0 8.0 38.4 5,376,000 3

AH133

Herie: Eprex 2000 (8 syr)

247,233,800 5,452.50 1,259,944,625 993 925 1116 867 1282 1116CURRENT SALES POTENSI DR CONFIRM OBJECTIVE C1 2010

VALUE (s) UNIT © VALUE © JAN FEB MAR 667,800 89.6 14,958,720 5 5 5 5 8 8 500,850 112.0 18,698,400 5 5 5 5 8 8 1,335,600 90.0 15,025,500 20 10 20 10 22 15 333,900 80.0 13,356,000 3 3 5 5 7 8 1,001,700 44.8 7,479,360 3 3 5 5 7 6 333,900 37.3 6,232,800 10 8 12 10 15 12 834,750 60.0 10,017,000 5 5 5 8 8 10 1,669,500 180.0 30,051,000 20 10 20 10 22 15 - 8.0 4,800,000 0 0 0 0 5 3 - 40.0 5,600,000 10 6 10 10 10 10 - 20.0 2,800,000 5 5 5 5 8 10 3,339,000 208.0 34,725,600 40 35 50 35 60 55 834,750 16.0 2,671,200 10 8 10 10 15 12 333,900 40.0 6,678,000 5 3 5 5 8 5 500,850 144.0 24,040,800 5 8 5 5 8 8 - 172.8 24,192,000 40 30 40 30 40 30 - 43.2 25,920,000 0 0 0 0 10 5 - 48.0 6,720,000 10 6 10 6 10 6 2,504,250 96.0 16,027,200 15 10 15 10 18 10 - 96.0 13,440,000 10 0 10 0 20 14 - 9.6 5,760,000 0 0 0 0 2 1 500,850 24.0 4,006,800 3 3 3 3 5 5 1,502,550 48.0 8,013,600 5 5 5 5 8 8 - 28.8 4,032,000 5 5 5 5 5 8 500,850 24.0 4,006,800 3 3 3 3 5 3 - 8.0 4,800,000 0 0 0 0 1 1 500,850 60.0 10,017,000 3 3 3 3 5 3 - 36.0 15,840,000 0 0 0 0 0 0 27,775,000 96.0 48,480,000 20 9 20 10 20 32 - 36.0 15,840,000 0 0 0 0 0 0 - 45.0 19,800,000 0 0 0 0 0 0 1,020,000 16.0 4,080,000 6 0 8 10 8 0 - 37.5 16,500,000 0 0 0 0 0 0 - 72.0 31,680,000 0 0 9 0 15 23 30,300,000 213.3 107,733,333 60 90 90 60 90 150 - 30.0 13,200,000 0 0 0 0 0 0 - 36.0 15,840,000 0 0 0 0 0 0 - 36.0 15,840,000 0 0 0 0 0 0 - 36.0 15,840,000 0 0 0 0 0 0 1,320,000 72.0 31,680,000 0 0 9 0 15 0 505,000 24.0 12,120,000 6 3 6 6 6 16 75,750,000 60.0 30,300,000 30 60 40 72 50 18

30,300,000 160.0 80,800,000 25 25 25 45 - 40.0 20,200,000 3 3 3 - 20.0 10,100,000 3 3 3

2,504,250 50.0 8,347,500 8 8 8 4 8 31,400,000 360.0 10,080,000 30 25 30 25 35 25

500,850 26.7 4,452,000 5 8 5 4 5 3 333,900 26.7 4,452,000 5 10 10 6 10 3 - 26.7 4,452,000 10 10 10 8 10 7 4,173,750 30.0 5,008,500 30 35 30 25 30 25 4,173,750 40.0 6,678,000 15 13 15 11 15 12 3,000,000 24.0 14,400,000 15 15 15 12 15 27 667,800 30.0 5,008,500 10 10 10 8 15 5 - 106.7 17,808,000 40 40 40 40 45 35 117,370 160.0 18,779,200 3 2 3 1 3 1 5,843,250 42.7 7,123,200 5 8 5 8 7 5 1,400,000 40.0 1,120,000 35 25 35 40 35 30 834,750 40.0 6,678,000 3 3 4 5 4 5 500,850 6.4 1,068,480 4 3 4 5 4 5 1,001,700 80.0 13,356,000 15 15 15 10 15 10 2,337,300 30.0 5,008,500 20 20 20 15 20 15

- 6.4 179,200 5 0 5 0 5 0

600,000 12.0 7,200,000 40 40 50 50 50 60 1,200,000 8.0 4,800,000 40 47 40 50 50 53 1,200,000 12.0 7,200,000 40 40 40 30 50 25

1,168,650 180.0 30,051,000 30 30 30 12 40 10 1,669,500 36.0 6,010,200 22 22 22 11 22 22

3,005,100 180.0 30,051,000 30 17 30 21 30 21 1,335,600 240.0 40,068,000 30 20 30 22 30 24

0 4.8 2,880,000 1 0 1 0 1 03,339,000 160.0 26,712,000 10 17 25 15 30 18

834,750 80.0 13,356,000 5 8 5 5 5 9 1,875,000 8.0 3,000,000 2 1 2 4 3 2

0 8.0 4,800,000 1 0 1 1 1 1 667,800 80.0 13,356,000 5 10 5 8 5 6 1,125,000 4.8 1,800,000 2 1 2 2 3 1

600,000 14.4 8,640,000 4 1 5 5 8 6 600,000 8.0 4,800,000 1 0 1 1 1 1 500,850 80.0 13,356,000 5 3 5 3 5 3 700,000 28.8 4,032,000 20 22 25 18 28 20 1,400,000 38.4 5,376,000 20 24 30 0 30 10 500,850 80.0 13,356,000 5 3 5 3 5 3 - 9.6 5,760,000 1 0 1 0 1 0 600,000 9.6 5,760,000 1 0 1 0 1 0 774,000 28.0 7,224,000 3 6 3 4 3 6 3,160,000 14.0 5,530,000 3 4 3 4 3 4 1,836,000 14.0 8,568,000 2 2 2 2 2 2

1,224,000 8.4 5,140,800 2 3 2 2 2 3 2,370,000 11.2 4,424,000 3 3 3 0 3 4 516,000 22.4 5,779,200 5 3 5 7 5 8 586,850 9.6 1,126,752 2 2 2 4 2 6

469,480 4.0 469,480 2 2 2 2 2 4 420,000 38.4 5,376,000 5 3 5 3 5 5

906.9% ### 563.6% 704.6%

102 86 198 152

5265 7175 4230 7950 3745 7760 43901384 1071 959,507,030 1294 1053 1435 846 1590 749 1552 878

OBJECTIVE C1 2010 OBJECTIVE C2 2010APR VALUE (c1) MAY JUNE JULY AUG

8 8 4,340,700 5 4 5 3 5 3 5 48 3 3,505,950 5 5 5 3 8 3 5 3

25 15 8,347,500 25 8 25 8 30 5 30 88 5 3,505,950 5 5 5 5 5 5 28 5 3,172,050 5 5 5 5 8 6 5 6

15 5 5,843,250 8 4 8 2 8 4 8 28 5 4,674,600 5 8 5 5 5 5 5 5

25 15 8,347,500 25 15 25 15 30 10 30 105 3 3,600,000 3 3 3 2

10 6 4,480,000 14 20 20 208 10 4,200,000 8 8 8 8

60 40 27,546,750 65 50 70 30 70 23 70 2015 10 6,678,000 8 10 8 5 8 5 5 57 2 2,504,250 3 2 3 2 5 2 5 28 5 4,340,700 5 3 5 3 8 3 5 3

50 80 23,800,000 60 60 70 7015 12 10,200,000 20 30 35 3510 5 3,220,000 15 15 20 2020 15 7,512,750 20 25 25 15 25 15 30 1520 12 3,640,000 40 40 50 502 1 1,200,000 3 3 3 25 5 2,671,200 3 3 3 3 5 3 3 38 10 4,674,600 3 23 3 13 5 13 5 95 5 3,220,000 8 8 5 55 3 2,003,400 3 3 3 3 4 3 3 31 1 1,200,000 1 1 1 15 5 2,337,300 3 3 3 3 4 3 3 33 0 0 0 0 0 0

20 32 41,915,000 34 69 38 132 38 75 36 559 0 0 0 0 0 00 0 0 0 0 0 38 0 2,550,000 12 12 12 12 40 0 0 0 0 0 0

21 0 10,120,000 15 20 24 2490 120 212,100,000 90 90 100 30 120 60 100 600 0 0 0 0 0 00 0 0 0 0 0 30 0 0 0 0 0 00 0 0 0 0 0 0

15 0 0 10 10 15 15 13 15 36 0 12,625,000 10 3 12 2 14 2 16 1

60 30 90,900,000 70 66 80 84 80 52 80 150

25 25 35,350,000 35 45 35 50 35 20 35 603 0 3 3 3 33 0 3 3 3 38 3 3,005,100 3 10 15 10 15 5 10 15

35 40 3,220,000 35 50 35 10 40 30 40 505 3 3,005,100 3 3 15 3 15 3 5 3

10 5 4,006,800 3 10 13 10 15 5 10 1510 5 5,008,500 5 7 12 7 14 5 8 535 30 19,199,250 35 25 45 40 45 40 5015 18 13,932,000 20 3 20 4 20 12 20 715 31 33,575,000 20 13 20 3 20 36 20 1715 6 4,841,550 20 6 20 6 25 6 25 450 50 27,546,750 55 303 4 938,960 5 1 5 1 5 5 17 3 4,006,800 3 4 8 5 8 5 5 4

35 40 3,780,000 35 50 35 10 40 30 40 504 5 3,005,100 3 4 4 3 3 3 3 35 4 2,838,150 3 3 3 3 5 3 4 3

20 13 8,013,600 20 8 25 8 25 10 20 620 20 11,686,500 20 24 25 24 25 28 25 14

5 0 0 10 10 10 10

50 45 32,555,250 50 57 50 55 50 37 40 1460 42 32,054,400 50 42 60 18 50 37 40 3350 26 20,200,950 25 23 40 13 50 11 60 840 0 8,681,400 5 16 20 9 30 10 60 722 11 11,018,700 22 25 33 25 33 25 33 1030 23 13,689,900 30 23 30 13 35 20 50 1840 24 15,025,500 20 18 40 12 50 10 50 81 1 600,000 1 1 1 1 1 1

30 15 10,851,750 15 20 20 21 30 22 30 208 10 5,342,400 8 9 5 4 8 7 5 53 2 3,375,000 1 5 1 6 1 2 1 51 2 2,400,000 1 2 1 2 1 18 7 5,175,450 8 9 5 4 8 6 5 43 1 1,875,000 4 4 4 5 4 2 4 3

10 7 11,400,000 5 5 6 6 7 2 7 11 1 1,800,000 1 1 1 1 1 1 15 3 2,003,400 5 3 3 5 5 5 5 3

28 12 10,080,000 28 17 28 13 28 2 28 535 17 7,140,000 25 30 28 20 30 4 30 105 3 2,003,400 5 3 3 5 5 5 5 31 3 1,800,000 1 2 1 2 1 1 12 6 3,600,000 1 2 1 3 1 1 1 13 6 5,676,000 6 5 6 7 4 7 33 4 6,320,000 5 5 5 1 6 6 6 82 4 6,120,000 2 5 3 5 3 4 3 32 4 7,344,000 2 5 3 4 3 4 3 23 4 4,345,000 3 5 3 1 3 5 3 65 4 5,676,000 5 4 5 5 3 5 22 4 938,960 4 2 4 4 4 3 4 5

2 2 938,960 3 3 3 3 2 3 45 0 1,540,000 5 5 5 2 5 5 3

862.67% 870% ### 941%

150 165 185 165

1,448,721,060 1558 1748 1882 1851 1,728,451,580 OBJECTIVE C2 2010 OBJECTIVE C3 2010

VALUE (c2) SEPT OCT NOV DEC VALUE (c3)

3,339,000 2,337,300 5 5 5 3 3,005,1003,839,850 2,337,300 5 5 5 3 3,005,100

18,364,500 4,841,550 35 40 45 50 28,381,5003,339,000 2,003,400 5 5 5 3 3,005,1003,839,850 3,672,900 5 5 8 3 3,505,9505,342,400 2,003,400 5 5 8 3 3,505,9503,339,000 3,839,850 5 5 5 3 3,005,100

18,364,500 8,347,500 35 40 45 50 28,381,5006,600,000 0 1 3 5 5 8,400,000

10,360,000 0 20 20 20 20 11,200,0004,480,000 0 5 5 5 5 2,800,000

45,911,250 20,534,850 75 80 85 90 55,093,5004,841,550 4,173,750 5 5 8 3 3,505,9502,671,200 1,335,600 3 4 5 3 2,504,2503,839,850 2,003,400 5 8 8 3 4,006,800

36,400,000 0 80 80 90 100 49,000,00072,000,000 0 35 38 35 35 85,800,000

9,800,000 0 25 25 30 30 15,400,00016,695,000 11,686,500 30 35 40 30 22,538,25025,200,000 0 50 50 50 50 28,000,000

6,600,000 0 1 1 2 4 4,800,0002,337,300 2,003,400 3 3 3 3 2,003,4002,671,200 9,683,100 5 5 5 3 3,005,1003,640,000 0 5 5 5 5 2,800,0002,170,350 2,003,400 3 3 3 3 2,003,4002,400,000 0 1 1 2 2 3,600,0002,170,350 2,003,400 3 3 3 3 2,003,400

0 0 0 0 0 0 073,730,000 167,155,000 36 38 30 40 72,720,000

0 0 0 0 0 0 01,320,000 0 0 0 0 0 0

12,240,000 1,020,000 12 12 8 11 10,965,0000 0 0 0 0 0 0

36,520,000 0 35 38 36 35 63,360,000207,050,000 121,200,000 100 120 137 120 240,885,000

0 0 0 0 0 0 01,320,000 0 0 0 0 0 0

0 0 0 0 0 0 00 0 0 0 0 0 0

22,000,000 13,640,000 15 15 21 20 31,240,00026,260,000 4,040,000 16 20 20 24 40,400,000

156,550,000 177,760,000 80 90 90 90 176,750,000

70,700,000 88,375,000 45 45 45 45 90,900,0006,060,000 0 3 3 3 3 6,060,0006,060,000 0 3 3 3 3 6,060,0007,178,850 6,678,000 10 10 10 5 5,843,2504,200,000 3,920,000 40 45 50 60 5,460,0006,344,100 2,003,400 7 10 7 5 4,841,5506,844,950 6,678,000 10 10 10 5 5,843,2506,511,050 4,006,800 8 5 5 3 3,505,950

27,546,750 19,199,250 40 45 55 45 30,885,75020,640,000 6,708,000 20 25 25 25 24,510,00031,600,000 27,255,000 25 30 35 36 49,770,00015,025,500 3,672,900 30 30 30 40 21,703,500

9,182,250 5,008,500 02,347,400 352,110 7 7 7 7 3,286,3604,006,800 3,005,100 5 5 3 3 2,671,2004,200,000 3,920,000 40 45 50 60 5,460,0002,170,350 2,170,350 3 3 3 3 2,003,4002,504,250 2,003,400 3 3 3 3 2,003,400

15,025,500 5,342,400 20 30 30 30 18,364,50015,860,250 15,025,500 25 30 30 30 19,199,250

1,120,000 0 15 15 15 15 1,680,000

31,720,500 27,212,850 45 50 60 70 37,563,75033,390,000 21,703,500 40 60 65 70 39,233,25029,216,250 9,182,250 50 60 65 70 40,902,75019,199,250 7,011,900 50 60 65 70 40,902,75020,200,950 14,190,750 22 33 30 25 18,364,50024,207,750 12,354,300 40 40 60 45 30,885,75026,712,000 8,013,600 40 50 60 50 33,390,000

2,400,000 1,200,000 1 1 1 1 2,400,00015,860,250 13,856,850 20 30 30 20 16,695,000

4,340,700 4,173,750 10 10 12 10 7,011,9001,500,000 6,750,000 1 1 1 1 1,500,0002,400,000 2,400,000 1 1 1 1 2,400,0004,340,700 3,839,850 10 10 12 10 7,011,9006,000,000 5,250,000 4 4 4 4 6,000,000

15,000,000 8,400,000 5 6 7 5 13,800,0002,400,000 1,800,000 1 1 1 1 2,400,0003,005,100 2,671,200 5 5 5 5 3,339,000

15,680,000 5,180,000 28 28 30 30 16,240,00015,820,000 8,960,000 25 30 30 30 16,100,000

3,005,100 2,671,200 5 5 5 5 3,339,0002,400,000 3,000,000 1 1 1 1 2,400,0002,400,000 4,200,000 1 1 1 1 2,400,0006,708,000 3,096,000 7 7 7 7 7,224,0008,690,000 7,900,000 6 6 6 6 9,480,0006,732,000 10,404,000 3 3 3 3 7,344,0006,732,000 9,180,000 3 3 3 3 7,344,0004,740,000 6,715,000 5 5 5 5 7,900,0005,160,000 2,322,000 7 7 7 7 7,224,0001,877,920 1,643,180 5 5 5 5 2,347,400

1,408,440 1,056,330 4 4 4 4 1,877,9202,800,000 1,400,000 5 5 5 5 2,800,000

944.24% 920.00% 965.13% 949.23%

165 190 195 195

4,136,679,670 19.62%

CATATAN

10,684,800 4% 7%10,350,900 3% 6%55,093,500 9% 37%

9,850,050 3% 7%10,517,850 13% 14%14,691,600 5% 24%11,018,700 8% 11%55,093,500 6% 18%18,600,000 0% 39%26,040,000 0% 47%11,480,000 0% 41%

128,551,500 10% 37%15,025,500 31% 56%

7,679,700 5% 12%12,187,350 2% 5%

109,200,000 0% 45%168,000,000 0% 54%

28,420,000 0% 35%46,746,000 16% 24%56,840,000 0% 35%12,600,000 0% 18%

7,011,900 13% 15%10,350,900 19% 11%

9,660,000 0% 20%6,177,150 13% 13%7,200,000 0% 13%6,511,050 5% 5%

0 0% 0%188,365,000 57% 32%

0 0% 0%1,320,000 0% 1%

25,755,000 25% 53%0 0% 0%

110,000,000 0% 29%660,035,000 28% 51%

0 0% 0%1,320,000 0% 1%

0 0% 0%0 0% 0%

53,240,000 4% 14%79,285,000 4% 55%

424,200,000 250% 117%

TOTAL OBJ 2010

Curr Sales VS Potensi

Objective VS Potensi

196,950,000 38% 20%12,120,000 0% 5%12,120,000 0% 10%16,027,200 30% 16%12,880,000 14% 11%14,190,750 8% 44%16,695,000 8% 48%15,025,500 0% 19%77,631,750 83% 99%59,082,000 63% 67%

114,945,000 21% 61%41,570,550 7% 50%36,729,000 38% 64%

6,572,720 44% 66%10,684,800 82% 82%13,440,000 0% 38%

7,178,850 13% 35%7,345,800 31% 52%

41,403,600 31% 33%46,746,000 3% 50%

2,800,000 0% 81%

101,839,500 8% 36%104,677,650 25% 48%

90,319,950 17% 52%68,783,400 4% 19%49,584,150 28% 69%68,783,400 10% 19%75,127,500 3% 16%

5,400,000 0% 16%43,407,000 13% 14%16,695,000 6% 10%

6,375,000 63% 18%7,200,000 0% 13%

16,528,050 5% 10%13,875,000 63% 64%40,200,000 7% 39%

6,600,000 13% 11%8,347,500 4% 5%

42,000,000 17% 87%39,060,000 26% 61%

8,347,500 4% 5%6,600,000 0% 10%8,400,000 10% 12%

19,608,000 11% 23%24,490,000 57% 37%20,196,000 21% 20%21,420,000 24% 35%16,985,000 54% 32%18,060,000 9% 26%

5,164,280 52% 38%

4,225,320 100% 75%7,140,000 8% 11%

Key

#REF!

#REF!

Activities by Dr Project32

No. PSR Dokter Activity 1 Activity 2

1 Haspi Firdaus L. Tandy Sutanto 5.25 PD Ultracet

2 Haspi Firdaus David Hariadi 5.25 PD Ultracet

3 Haspi Firdaus Fritz Nahusuli 6.25 PD Ultracet

4 Haspi Firdaus Ramelan 7 PD Ultracet

5 Haspi Firdaus Satria Sewu 5 PD Fentanyl

7 Haspi Firdaus Benida 5.5 PD Fentanyl

8 Haspi Firdaus Rudi Peleh 3.5 PD Fentanyl

9 Haspi Firdaus Dwiana Sulistyanti 6.75 PD Fentanyl

10 Fina Julianti Indra Peni 3.75 PP Ultracet

11 Fina Julianti Hendra Gunawan 7.25 RTD Ultracet

12 Fina Julianti Sarmauli Sitorus 5.5 RTD Ultracet

13 Fina Julianti Prasetyawan Widiayanto 4.5 PP Ultracet

14 Fina Julianti HM Darwis Dahlan 12 PP Ultracet

15 Fina Julianti M Yunus 5.25 PP Fentanyl

16 Fina Julianti Agus Tribudhi Tjahyono 2.75 PP Fentanyl

17 Bhakti Setiawan Santosa Tanuseputra 4.5 PD Ultracet

18 Bhakti Setiawan Izaak Zoelkarnain Akbar 8.5 PD Ultracet

19 Bhakti Setiawan Zairin Noor Helmi 1.5 PD Ultracet

20 Bhakti Setiawan Andreas Siagian 1.5 PD Ultracet

21 Bhakti Setiawan David Tanaputra 6 PD Ultracet

22 Bhakti Setiawan Dedy Rasyidan Yulizar 6.5 PD Ultracet

23 Bhakti Setiawan Agus Yuwono 3 PD Ultracet

24 Bhakti Setiawan I Gde Sudaadnyana 2.5 PD Ultracet

25 Bhakti Setiawan Darwin Prenggono 2.75 PD Durogesic

26 Bhakti Setiawan Basuki Rachmad 2.75 PD Fentanyl

28 Bhakti Setiawan Zainuddin Arpandy 3 PD Topamax

29 Fajar Yuliani Tri Prabowo 1 PD Eprex

30 Fajar Yuliani Kuntjoro yakti 8.33 PD Eprex

31 Fajar Yuliani Effendy Pardede 6.33 PD Eprex

32 Fajar Yuliani Dyah Sawitri 1 PD Eprex

33 Fajar Yuliani Lianda Siregar 5 PD Doribax

34 Fajar Yuliani Carta A Gunawan 6.33 PD Doribax

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

Activity 3

PP Ultracet

PP Ultracet

PP Ultracet

PP Ultracet

PP Fentanyl

PP Fentanyl

PP Fentanyl

PP Fentanyl

Home Visit

Home Visit

Home Visit

Home Visit

Home Visit

Home Visit

Home Visit

PP Ultracet

PP Ultracet

PP Ultracet

PP Ultracet

PP Ultracet

PP Ultracet

PP Ultracet

PP Ultracet

PP Durogesic

PP Fentanyl

PP Topamax

PP Eprex

PP Eprex

PP Eprex

PP Eprex

Chemotherapi & Infectious D, Singapura, December

Konggres Respiratory, Manila, November

Activity 4

Eduacational Support (TBD)

ATLS jakarta (maret)

ATLS jakarta (maret)

ESICIM, October Nov'10

IDSAI Medan Juli 2010

IDSAI Medan Juli 2010

6th National Basic Arthroplasty Course Kuantan 2010



The First Jakarta Uro-Oncology Update 2010, February 2010

ATLS in Conjunction with 3rd Meeting of Region XVI (Asia Pacific), March 2010

7th International Annual Meeting of ISOA ISRA, February 2010

KONAS IDSAI IX MEDAN, July 2010

Temu Ilmiah Rheumatologi, Borobudur Jakarta 16-18 April'10

AOE COE, Agrowisata Malang 17-19 Juni'10



Educational Support (TBD)

Fiesta Urobaya, Hotel Bumi,Surabaya 29 juli - 1 agustus 2010

JDM hotel Mercure Jakarta 13-14 Nov 2010



Konas IDSAI Medan Juli'10


Speaker Patient Gathering

PERNEFRI, Semarang, October



The 17th International Symposium On Critical care & Emergency Medicine 2010 Bali

Activity 5 A&P Act 1A&P Act 2A&P Act 3A&P Act 4

APCN, Korsel, June

NAMA PSR TERRITORY NAMA DOKTER VSNCI CII CIII

SMRD ASA Lianda Siregar, SpPD Ultracet SMRD ASA Kuntjoro Yakti, SpPD Ultracet SMRD ASA 1 1 1 Fritz Nahusuli, SpB Ultracet SMRD ASA Ishaq Hardiansyah, SpBU Ultracet SMRD ASA Arie Ibrahim, SpBS Ultracet SMRD ASA Eliawati Hadibrata, SpS Ultracet SMRD ASA Maruf, SpBS Ultracet SMRD ASA 1 1 1 David H Masjhoer, SpOT Ultracet SMRD ASA 1 Benida, SpAn Durogesic SMRD ASA 1 Benida, SpAn Fentanyl SMRD ASA Abdul Haris, SpAn Fentanyl SMRD ASA 1 1 1 L Tandi Susanto Ultracet SMRD ASA Maria Gabriela Ultracet SMRD ASA Mangalindung, SpB Ultracet SMRD ASA 1 1 Gregorius Tekwan, SpOT Ultracet SMRD ASA 1 1 1 Rudi Peleh, SpAn Fentanyl SMRD ASA 1 1 1 Satria, SpAn Durogesic SMRD ASA 1 1 1 Dwiana Sulistyanti, SpAn Fentanyl SMRD ASA 1 1 1 Ramelan Adiputra Nur, SpB Ultracet SMRD ASA 1 1 1 Satria, SpAn Fentanyl SMRD ASA Issaq Hardiansyah, SpBU Durogesic SMRD ASA Swandi Bustani Ultracet SMRD ASA Andi Majid, SpPD Ultracet SMRD ASA Fernata bangun, SpAn Fentanyl SMRD ASA Sopianita tavip Ultracet SMRD ASA Boyke, SpU Durogesic SMRD ASA Boyke, SpU Ultracet

Fajar Yuliani Eliawati Hadibrata, SpS Doribax Fajar Yuliani 1 1 1 Kuntjoro Yakti, SpPD Eprex Fajar Yuliani Satria,SpAn Doribax Fajar Yuliani Enny Pasolang, SpPD Doribax Fajar Yuliani 1 1 1 Dyah Sawitri, SpPD Eprex Fajar Yuliani Andi Majid Doribax Fajar Yuliani 1 1 1 Lianda Siregar, SpPD Doribax Fajar Yuliani 1 1 1 Tri Prabowo, SpPD Eprex Fajar Yuliani AZ Ma'ruf Doribax Fajar Yuliani Donni Doribax Fajar Yuliani Aswad Muhammad Doribax Fajar Yuliani Arie Ibrahim, SpBS Doribax Fajar Yuliani 1 1 1 Carta A Gunawan, SpPD Doribax Fajar Yuliani 1 1 1 Effendy Pardede, SpPD Eprex Margareta BPP AI-BIO 1 1 1 Edi Iskandar Dr.,SpPD Eprex Margareta BPP AI-BIO 1 1 1 Lukman Hatta Dr.,SpPD Eprex Margareta BPP AI-BIO Nono Maturangan Dr.,SpPD Eprex Margareta BPP AI-BIO Nani Prasedjo Dr.,SpPD Eprex Vacant (eks Fina) BPP ASA Adi Aryanto, SpOT Ultracet Vacant (eks Fina) BPP ASA 1 1 1 Agus Tri Budi W, SpAN Fentanyl

Doctor Project 2010

Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi)Vacant (eks Haspi) SMRD AI-

BIOSMRD AI-BIOSMRD AI-BIOSMRD AI-BIOSMRD AI-BIOSMRD AI-BIOSMRD AI-BIOSMRD AI-BIOSMRD AI-BIOSMRD AI-BIOSMRD AI-BIOSMRD AI-BIOSMRD AI-BIOSMRD AI-BIO

Vacant (eks Fina) BPP ASA 1 1 Alexander, SpOT Ultracet Vacant (eks Fina) BPP ASA Doddy Priambodo, SpBS Ultracet Vacant (eks Fina) BPP ASA Edi Iskandar, SpPD Ultracet Vacant (eks Fina) BPP ASA 1 1 1 Hendra Gunawan, SpS Ultracet Vacant (eks Fina) BPP ASA 1 1 1 Hendra Gunawan, SpS Topamax25 Vacant (eks Fina) BPP ASA 1 1 1 Hendra Gunawan, SpS Topamax50 Vacant (eks Fina) BPP ASA 1 1 1 HM Darwis Dahlan, SpB Ultracet Vacant (eks Fina) BPP ASA 1 Indra Peni, SpOT Ultracet Vacant (eks Fina) BPP ASA Jaya Mualimin, SpKJ haldec Vacant (eks Fina) BPP ASA Lukman Hatta, SpPD Ultracet Vacant (eks Fina) BPP ASA 1 1 1 M. Yunus, SpAN Fentanyl Vacant (eks Fina) BPP ASA Nani Prasedjo, SpPD Ultracet Vacant (eks Fina) BPP ASA Nono Maturangan, SpPD Ultracet Vacant (eks Fina) BPP ASA 1 1 1 Prasetiawan, SpBU Ultracet Vacant (eks Fina) BPP ASA 1 1 1 Sarmauli Sitorus, SpS Ultracet Vacant (eks Fina) BPP ASA Sentot, SpBO Fentanyl

BJM ASA 1 1 1 Santosa Tanuseputra Ultracet BJM ASA 1 1 1 Izaak Zoelkarnain Akbar, SpOT, FIC Ultracet BJM ASA 1 1 1 Zairin Noor Helmi,SpOT, K.SPINE Ultracet BJM ASA 1 1 1 Andreas Siagiaan,SpOT Ultracet BJM ASA 1 1 1 David Tanaputra Ultracet BJM ASA 1 1 1 Dedy Rasyidan Yulizar,SpU Ultracet BJM ASA 1 1 1 Agus Yuwono,SpPD Ultracet BJM ASA 1 1 1 Agus Yuwono,SpPD Durogesic25 BJM ASA 1 1 1 I Gde Sudaadnyana,SpPD Ultracet BJM ASA Budianto,SpBOnk Ultracet BJM ASA Budianto,SpBOnkBJM ASA Budianto,SpBOnk Durogesic25 BJM ASA Djohan Sebastian,SpPD Ultracet BJM ASA Djohan Sebastian,SpPDBJM ASA 1 1 1 Darwin Prenggono,SpPD Durogesic25 BJM ASA Tjahyo Kelono Utomo,SpB Durogesic25 BJM ASA Wiwit Agung SNC,SpPD Ultracet BJM ASA 1 1 1 Basuki Rachmad,SpAn Fentanyl2ml BJM ASA Kararawji,SpAn Fentanyl2ml BJM ASA Herudento,SpPD Ultracet BJM ASA Herudento,SpPD Durogesic25 BJM ASA Binsar Parhusip,SpB Durogesic25 BJM ASA 1 1 1 Zainuddin Arpandy,Sp.S Topamax25 BJM ASA 1 1 1 Zainuddin Arpandy,Sp.S Topamax50 BJM ASA 1 1 1 Zainuddin Arpandy,Sp.SBJM ASA Aris Geson,SpSBJM ASA Oscar Nurhadi,SpS Topamax50 BJM ASA Oscar Nurhadi,SpS Topamax25 BJM ASA Yulizar Darwis,SpKJ Haldec BJM ASA Herawaty Haldec BJM ASA Retna Utami,SpAn Fentanyl2ml

Vacant (Eks Gusti)BJM AI-BIO 1 1 1 Djohan Sebastian Dr.,SpPD EprexVacant (Eks Gusti)BJM AI-BIO Kasan Wongdjaja Dr.,SpPD EprexVacant (Eks Gusti)BJM AI-BIO Ferry Dharmawan Dr. Eprex

Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti)

Durogesic12,5 Vacant (eks

Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti)

Durogesic12,5 Vacant (eks

Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti)

Topamax100 Vacant (eks Bhakti)

Topamax100 Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti) Vacant (eks Bhakti)

Vacant (Eks Gusti)BJM AI-BIO David Tanaputra Dr. EprexVacant (Eks Gusti)BJM AI-BIO I Gde Sudaadnyana Dr.,SpPD EprexVacant (Eks Gusti)BJM AI-BIO Nurul Aina Dr.,SpPD EprexVacant (Eks Gusti)BJM AI-BIO Rudiansyah Dr.,SpPD Eprex

JML JML Hari JMLHNA

CLASS NO of CASE per DAY

Pasien TAB/R Kerja TAB/BOX PASIEN ASUMSI CONFIRM UNIT

15 28 24 30 166,950 Menengah keatas 5 4 112 20 28 24 30 166,950 Menengah keatas 6 5 134 13 15 20 30 166,950 Menengah keatas 11 9 110 15 15 20 30 166,950 Menengah keatas 15 8 150 10 28 24 30 166,950 Menengah keatas 3 2 67 30 28 20 30 166,950 Menengah keatas 5 2 93 10 15 20 30 166,950 Menengah keatas 15 6 150 25 15 20 30 166,950 Menengah keatas 15 18 150 10 1 20 5 600,000 Menengah keatas 5 2 20 10 1 20 5 140,000 Menengah keatas 10 10 40 5 1 20 5 140,000 Menengah keatas 5 5 20

35 20 24 30 166,950 Menengah keatas 10 13 160 20 10 24 30 166,950 Menengah 2 2 16 10 10 24 30 166,950 Menengah 5 5 40 15 15 24 30 166,950 Menengah 10 12 120 20 2 24 5 140,000 Menengah keatas 15 18 144 30 1 24 5 600,000 Menengah 10 9 48 15 1 24 5 140,000 Menengah 10 10 48 15 15 24 30 166,950 Menengah 10 8 120 30 1 24 5 140,000 Menengah 15 20 72 5 1 24 5 600,000 Menengah Keatas 5 2 24

20 10 24 30 166,950 Menengah 4 3 32 10 20 24 30 166,950 Menengah 6 3 96 10 1 24 5 140,000 Menengah 10 6 48 10 10 24 30 166,950 Menengah 6 3 48 8 1 20 5 600,000 Menengah 5 2 20 8 30 20 30 166,950 Menengah 5 3 100

30 15 24 1 440,000 Menengah keatas 1 0 360 15 8 24 6 505,000 Menengah keatas 5 3 160 10 15 24 1 440,000 Menengah keatas 1 0 360 15 15 15 1 440,000 Menengah keatas 1 0 4 15 4 24 6 255,000 Menengah keatas 2 1 32 5 15 25 1 440,000 Menengah keatas 1 0 375

10 15 24 1 440,000 Menengah keatas 2 0 720 20 8 20 6 505,000 Menengah keatas 10 8 267 10 15 20 1 440,000 Menengah keatas 1 0 300 5 15 24 1 440,000 Menengah keatas 1 0 360

10 15 24 1 440,000 Menengah keatas 1 0 360 10 15 24 1 440,000 Menengah keatas 1 0 360 20 15 24 1 440,000 Menengah keatas 2 0 720 10 4 24 6 505,000 Menengah keatas 2 2 32 20 1 20 1 505,000 Menengah keatas 8 3 160 25 1 20 1 505,000 Menengah keatas 12 8 240 25 1 20 1 505,000 Menengah keatas 5 2 100 20 1 20 1 505,000 Menengah keatas 3 1 60 8 15 20 30 166,950 Menengah keatas 7 5 70

15 1 24 1 28,000 Menengah 15 15 360

POTENSI DR ASUMSI

10 15 20 30 166,950 Menengah 8 7 67 10 15 20 30 166,950 Menengah keatas 5 4 40 25 20 24 30 166,950 Menengah keatas 5 4 67 30 20 24 30 166,950 Menengah 10 8 50 30 14 24 60 258,000 Menengah 10 10 107 30 14 24 60 395,000 Menengah 10 10 40 10 15 20 30 166,950 Menengah keatas 5 5 50 20 15 20 30 166,950 Menengah keatas 15 15 160 10 1 20 1 117,370 Menengah keatas 10 7 213 25 20 24 30 166,950 Menengah keatas 5 5 53 15 1 24 1 28,000 Menengah 15 15 67 10 20 20 30 166,950 Menengah keatas 4 3 80 15 20 20 30 166,950 Menengah keatas 3 4 22 15 15 20 30 166,950 Menengah keatas 9 8 120 20 20 24 30 166,950 Menengah keatas 10 7 50 15 1 24 1 28,000 Menengah 15 15 10 30 15 24 30 166,950 Menengah keatas 15 15 16 25 20 24 30 166,950 Menengah keatas 15 20 12 25 15 24 30 166,950 Menengah keatas 15 20 20 20 15 24 30 166,950 Menengah keatas 15 15 180 20 15 24 30 166,950 Menengah keatas 3 3 36 20 15 24 30 166,950 Menengah keatas 15 15 180 30 20 24 30 166,950 Menengah keatas 10 15 160 30 1 24 5 600,000 Menengah keatas 1 1 5 25 20 24 30 166,950 Menengah 10 10 160 12 15 20 30 166,950 Menengah keatas 5 8 50 12 1 20 5 375,000 Menengah keatas 2 2 8 12 1 20 5 600,000 Menengah keatas 2 2 8 20 20 24 30 166,950 Menengah 7 5 112 20 1 24 5 375,000 Menengah 1 1 5 20 1 24 5 600,000 Menengah keatas 5 3 24 15 1 20 5 600,000 Menengah keatas 2 2 8 10 20 24 30 166,950 Menengah 6 5 96 6 1 24 5 140,000 Menengah 6 6 29 8 1 24 5 140,000 Menengah 8 8 38

12 20 24 30 166,950 8 5 128 12 1 24 5 600,000 2 2 10 15 1 24 5 600,000 Menengah 3 2 14 50 14 24 60 258,000 Menengah keatas 7 5 39 50 7 24 60 395,000 Menengah keatas 7 5 20 50 7 24 60 612,000 Menengah keatas 7 5 20 10 7 24 60 612,000 Menengah 5 3 14 30 7 24 60 395,000 Menengah 5 4 14 30 14 24 60 258,000 Menengah 5 4 28 10 1 24 5 117,370 Menengah 3 2 14 10 1 20 5 117,370 Menengah 1 1 4 8 1 24 5 140,000 Menengah 8 8 38

20 1 24 1 505,000 Menengah 5 3 120 20 1 24 1 505,000 Menengah 2 1 48 15 1 24 1 505,000 Menengah 2 1 48

Menengah kebawahMenengah kebawah

20 1 24 1 505,000 Menengah 2 1 48 20 1 24 1 505,000 Menengah 2 1 48 15 1 20 1 505,000 Menengah 3 1 60 15 1 24 1 505,000 Menengah 2 1 48

CURRENT SALES POTENSI DR CONFIRM OBJECTIVE C1 2010

VALUE UNIT VALUE UNIT VALUE Jan Act Feb Act Mar Act Apr Act

18,698,400 4 667,800 90 14,958,720 5 5 5 5 8 8 8 822,438,080 3 500,850 112 18,698,400 5 5 5 5 8 8 8 318,364,500 8 1,335,600 90 15,025,500 20 10 20 10 22 15 25 1525,042,500 2 333,900 80 13,356,000 3 3 5 5 7 8 8 511,219,040 6 1,001,700 45 7,479,360 3 3 5 5 7 6 8 515,582,000 2 333,900 37 6,232,800 10 8 12 10 15 12 15 525,042,500 5 834,750 60 10,017,000 5 5 5 8 8 10 8 525,042,500 10 1,669,500 180 30,051,000 20 10 20 10 22 15 25 1512,000,000 - 8 4,800,000 0 0 0 0 5 3 5 3

5,600,000 - 40 5,600,000 10 6 10 10 10 10 10 62,800,000 - 20 2,800,000 5 5 5 5 8 10 8 10

26,712,000 20 3,339,000 208 34,725,600 40 35 50 35 60 55 60 402,671,200 5 834,750 16 2,671,200 10 8 10 10 15 12 15 106,678,000 2 333,900 40 6,678,000 5 3 5 5 8 5 7 2

20,034,000 3 500,850 144 24,040,800 5 8 5 5 8 8 8 520,160,000 - 173 24,192,000 40 30 40 30 40 30 50 8028,800,000 - 43 25,920,000 0 0 0 0 10 5 15 12

6,720,000 - 48 6,720,000 10 6 10 6 10 6 10 520,034,000 15 2,504,250 96 16,027,200 15 10 15 10 18 10 20 1510,080,000 - 96 13,440,000 10 0 10 0 20 14 20 1214,400,000 - 10 5,760,000 0 0 0 0 2 1 2 1

5,342,400 3 500,850 24 4,006,800 3 3 3 3 5 5 5 516,027,200 9 1,502,550 48 8,013,600 5 5 5 5 8 8 8 10

6,720,000 - 29 4,032,000 5 5 5 5 5 8 5 58,013,600 3 500,850 24 4,006,800 3 3 3 3 5 3 5 3

12,000,000 - 8 4,800,000 0 0 0 0 1 1 1 116,695,000 3 500,850 60 10,017,000 3 3 3 3 5 3 5 5

### - 36 15,840,000 0 0 0 0 0 0 3 080,800,000 55 ### 96 48,480,000 20 9 20 10 20 32 20 32

### - 36 15,840,000 0 0 0 0 0 0 9 01,540,000 - 45 19,800,000 0 0 0 0 0 0 0 08,160,000 4 1,020,000 16 4,080,000 6 0 8 10 8 0 8 0

### - 38 16,500,000 0 0 0 0 0 0 0 0### - 72 31,680,000 0 0 9 0 15 23 21 0### 60 ### 213 107,733,333 60 90 90 60 90 ### 90 ###### - 30 13,200,000 0 0 0 0 0 0 0 0### - 36 15,840,000 0 0 0 0 0 0 0 0### - 36 15,840,000 0 0 0 0 0 0 0 0### - 36 15,840,000 0 0 0 0 0 0 0 0### 3 1,320,000 72 31,680,000 0 0 9 0 15 0 15 0

16,160,000 1 505,000 24 12,120,000 6 3 6 6 6 16 6 080,800,000 150 ### 60 30,300,000 30 60 40 72 50 18 60 30

### 60 ### 160 80,800,000 25 25 25 45 25 2550,500,000 - 40 20,200,000 3 3 3 330,300,000 - 20 10,100,000 3 3 3 311,686,500 15 2,504,250 50 8,347,500 8 8 8 4 8 3 8 310,080,000 50 1,400,000 360 10,080,000 30 25 30 25 35 25 35 40

POTENSI DR ASUMSI

11,130,000 3 500,850 27 4,452,000 5 8 5 4 5 3 5 36,678,000 15 333,900 27 4,452,000 5 10 10 6 10 3 10 5

11,130,000 5 - 27 4,452,000 10 10 10 8 10 7 10 58,347,500 50 4,173,750 30 5,008,500 30 35 30 25 30 25 35 30

17,808,000 7 4,173,750 40 6,678,000 15 13 15 11 15 12 15 1824,000,000 17 3,000,000 24 14,400,000 15 15 15 12 15 27 15 31

8,347,500 4 667,800 30 5,008,500 10 10 10 8 15 5 15 626,712,000 - 107 17,808,000 40 40 40 40 45 35 50 5025,038,933 1 117,370 160 18,779,200 3 2 3 1 3 1 3 4

8,904,000 4 5,843,250 43 7,123,200 5 8 5 8 7 5 7 31,866,667 50 1,400,000 40 1,120,000 35 25 35 40 35 30 35 40

13,356,000 3 834,750 40 6,678,000 3 3 4 5 4 5 4 53,739,680 3 500,850 6 1,068,480 4 3 4 5 4 5 5 4

20,034,000 6 1,001,700 80 13,356,000 15 15 15 10 15 10 20 138,347,500 14 2,337,300 30 5,008,500 20 20 20 15 20 15 20 20

268,800 - 6 179,200 5 0 5 0 5 0 5 09,600,000 14 600,000 12 7,200,000 40 40 50 50 50 60 50 457,200,000 33 1,200,000 8 4,800,000 40 47 40 50 50 53 60 42

12,000,000 8 1,200,000 12 7,200,000 40 40 40 30 50 25 50 2630,051,000 7 1,168,650 180 30,051,000 30 30 30 12 40 10 40 0

6,010,200 10 1,669,500 36 6,010,200 22 22 22 11 22 22 22 1130,051,000 18 3,005,100 180 30,051,000 30 17 30 21 30 21 30 2326,712,000 8 1,335,600 240 40,068,000 30 20 30 22 30 24 40 24

2,880,000 0 5 2,880,000 1 0 1 0 1 0 1 126,712,000 20 3,339,000 160 26,712,000 10 17 25 15 30 18 30 15

8,347,500 5 834,750 80 13,356,000 5 8 5 5 5 9 8 103,000,000 5 1,875,000 8 3,000,000 2 1 2 4 3 2 3 24,800,000 0 8 4,800,000 1 0 1 1 1 1 1 2

18,698,400 4 667,800 80 13,356,000 5 10 5 8 5 6 8 71,800,000 3 1,125,000 5 1,800,000 2 1 2 2 3 1 3 1

14,400,000 1 600,000 14 8,640,000 4 1 5 5 8 6 10 74,800,000 1 600,000 8 4,800,000 1 0 1 1 1 1 1 1

16,027,200 3 500,850 80 13,356,000 5 3 5 3 5 3 5 34,032,000 5 700,000 29 4,032,000 20 22 25 18 28 20 28 125,376,000 10 1,400,000 38 5,376,000 20 24 30 0 30 10 35 17

21,369,600 3 500,850 80 13,356,000 5 3 5 3 5 3 5 35,760,000 - 10 5,760,000 1 0 1 0 1 0 1 38,640,000 1 600,000 10 5,760,000 1 0 1 0 1 0 2 6

10,113,600 3 774,000 28 7,224,000 3 6 3 4 3 6 3 67,742,000 8 3,160,000 14 5,530,000 3 4 3 4 3 4 3 4

11,995,200 3 1,836,000 14 8,568,000 2 2 2 2 2 2 2 48,568,000 2 1,224,000 8 5,140,800 2 3 2 2 2 3 2 45,530,000 6 2,370,000 11 4,424,000 3 3 3 0 3 4 3 47,224,000 2 516,000 22 5,779,200 5 3 5 7 5 8 5 41,690,128 5 586,850 10 1,126,752 2 2 2 4 2 6 2 4

469,480 4 469,480 4 469,480 2 2 2 2 2 4 2 25,376,000 3 420,000 38 5,376,000 5 3 5 3 5 5 5 0

60,600,000 23 ### 72 36,360,000 10 11 10 13 12 12 12 1424,240,000 - 24 12,120,000 24,240,000 8 4,040,000 24 12,120,000 5 10 5 5 5 5

24,240,000 - 12 6,060,000 24,240,000 - 12 6,060,000 30,300,000 - 10 5,050,000 24,240,000 - 12 6,060,000

OBJECTIVE C1 2010 OBJECTIVE CII 2010 OBJECTIVE C3 2010

VALUE (CI) Act CI May Act June Act July Act Aug Act Act CII Sept Oct

4,340,700 4,340,700 5 4 5 3 5 3 5 4 3,339,000 2,337,300 5 54,340,700 3,505,950 5 5 5 3 8 3 5 3 3,839,850 2,337,300 5 5

14,524,650 8,347,500 25 8 25 8 30 5 30 8 18,364,500 4,841,550 35 403,839,850 3,505,950 5 5 5 5 5 5 2 3,339,000 2,003,400 5 53,839,850 3,172,050 5 5 5 5 8 6 5 6 3,839,850 3,672,900 5 58,681,400 5,843,250 8 4 8 2 8 4 8 2 5,342,400 2,003,400 5 54,340,700 4,674,600 5 8 5 5 5 5 5 5 3,339,000 3,839,850 5 5

14,524,650 8,347,500 25 15 25 15 30 10 30 10 18,364,500 8,347,500 35 401,669,500 1,001,700 3 3 3 2 1,836,450 0 1 36,678,000 5,342,400 14 20 20 20 12,354,300 0 20 204,340,700 5,008,500 8 8 8 8 5,342,400 0 5 5

35,059,500 ### 65 50 70 30 70 23 70 20 45,911,250 ### 75 808,347,500 6,678,000 8 10 8 5 8 5 5 5 4,841,550 4,173,750 5 54,173,750 2,504,250 3 2 3 2 5 2 5 2 2,671,200 1,335,600 3 44,340,700 4,340,700 5 3 5 3 8 3 5 3 3,839,850 2,003,400 5 8

28,381,500 ### 60 60 70 70 43,407,000 0 80 804,173,750 2,838,150 20 30 35 35 20,034,000 0 35 386,678,000 3,839,850 15 15 20 20 11,686,500 0 25 25

11,352,600 7,512,750 20 25 25 15 25 15 30 15 16,695,000 ### 30 3510,017,000 4,340,700 40 40 50 50 30,051,000 0 50 50

667,800 333,900 3 3 3 2 1,836,450 0 1 12,671,200 2,671,200 3 3 3 3 5 3 3 3 2,337,300 2,003,400 3 34,340,700 4,674,600 3 23 3 13 5 13 5 9 2,671,200 9,683,100 5 53,339,000 3,839,850 8 8 5 5 4,340,700 0 5 52,671,200 2,003,400 3 3 3 3 4 3 3 3 2,170,350 2,003,400 3 3

333,900 333,900 1 1 1 1 667,800 0 1 12,671,200 2,337,300 3 3 3 3 4 3 3 3 2,170,350 2,003,400 3 3

500,850 0 0 0 0 0 0 0 0 013,356,000 ### 34 69 38 ### 38 75 36 55 24,374,700 ### 36 38

1,502,550 0 0 0 0 0 0 0 0 00 0 0 0 0 3 500,850 0 0 0

5,008,500 1,669,500 12 12 12 12 4 8,013,600 667,800 12 120 0 0 0 0 0 0 0 0 0

7,512,750 3,839,850 15 20 24 24 13,856,850 0 35 3855,093,500 ### 90 90 100 30 120 60 100 60 68,449,500 ### 100 120

0 0 0 0 0 0 0 0 0 00 0 0 0 0 3 500,850 0 0 00 0 0 0 0 0 0 0 0 00 0 0 0 0 0 0 0 0 0

6,511,050 0 10 10 15 15 13 15 3 8,347,500 5,175,450 15 154,006,800 4,173,750 10 3 12 2 14 2 16 1 8,681,400 1,335,600 16 20

30,051,000 ### 70 66 80 84 80 52 80 ### 51,754,500 ### 80 9016,695,000 ### 35 45 35 50 35 20 35 60 23,373,000 ### 45 45

2,003,400 0 3 3 3 3 2,003,400 0 3 32,003,400 0 3 3 3 3 2,003,400 0 3 35,342,400 3,005,100 3 10 15 10 15 5 10 15 7,178,850 6,678,000 10 10

21,703,500 ### 35 50 35 10 40 30 40 50 25,042,500 ### 40 45

VALUE (CII)

3,339,000 3,005,100 3 3 15 3 15 3 5 3 6,344,100 2,003,400 7 105,843,250 4,006,800 3 10 13 10 15 5 10 15 6,844,950 6,678,000 10 106,678,000 5,008,500 5 7 12 7 14 5 8 5 6,511,050 4,006,800 8 5

20,868,750 ### 35 25 45 40 45 40 50 27,546,750 ### 40 4510,017,000 9,015,300 20 3 20 4 20 12 20 7 13,356,000 4,340,700 20 2510,017,000 ### 20 13 20 3 20 36 20 17 13,356,000 ### 25 30

8,347,500 4,841,550 20 6 20 6 25 6 25 4 15,025,500 3,672,900 30 3029,216,250 ### 55 30 9,182,250 5,008,500

2,003,400 1,335,600 5 1 5 1 5 5 1 3,339,000 500,850 7 74,006,800 4,006,800 3 4 8 5 8 5 5 4 4,006,800 3,005,100 5 5

23,373,000 ### 35 50 35 10 40 30 40 50 25,042,500 ### 40 452,504,250 3,005,100 3 4 4 3 3 3 3 3 2,170,350 2,170,350 3 32,838,150 2,838,150 3 3 3 3 5 3 4 3 2,504,250 2,003,400 3 3

10,851,750 8,013,600 20 8 25 8 25 10 20 6 15,025,500 5,342,400 20 3013,356,000 ### 20 24 25 24 25 28 25 14 15,860,250 ### 25 30

3,339,000 0 10 10 10 10 6,678,000 0 15 1531,720,500 ### 50 57 50 55 50 37 40 14 31,720,500 ### 45 5031,720,500 ### 50 42 60 18 50 37 40 33 33,390,000 ### 40 6030,051,000 ### 25 23 40 13 50 11 60 8 29,216,250 9,182,250 50 6023,373,000 8,681,400 5 16 20 9 30 10 60 7 19,199,250 7,011,900 50 6014,691,600 ### 22 25 33 25 33 25 33 10 20,200,950 ### 22 3320,034,000 ### 30 23 30 13 35 20 50 18 24,207,750 ### 40 4021,703,500 ### 20 18 40 12 50 10 50 8 26,712,000 8,013,600 40 50

667,800 166,950 1 1 1 1 1 1 667,800 333,900 1 115,860,250 ### 15 20 20 21 30 22 30 20 15,860,250 ### 20 30

3,839,850 5,342,400 8 9 5 4 8 7 5 5 4,340,700 4,173,750 10 101,669,500 1,502,550 1 5 1 6 1 2 1 5 667,800 3,005,100 1 1

667,800 667,800 1 2 1 2 1 1 667,800 667,800 1 13,839,850 5,175,450 8 9 5 4 8 6 5 4 4,340,700 3,839,850 10 101,669,500 834,750 4 4 4 5 4 2 4 3 2,671,200 2,337,300 4 44,507,650 3,172,050 5 5 6 6 7 2 7 1 4,173,750 2,337,300 5 6

667,800 500,850 1 1 1 1 1 1 1 667,800 500,850 1 13,339,000 2,003,400 5 3 3 5 5 5 5 3 3,005,100 2,671,200 5 5

16,861,950 ### 28 17 28 13 28 2 28 5 18,698,400 6,177,150 28 2819,199,250 8,514,450 25 30 28 20 30 4 30 10 18,865,350 ### 25 30

3,339,000 2,003,400 5 3 3 5 5 5 5 3 3,005,100 2,671,200 5 5667,800 500,850 1 2 1 2 1 1 1 667,800 834,750 1 1834,750 1,001,700 1 2 1 3 1 1 1 1 667,800 1,168,650 1 1

2,003,400 3,672,900 6 5 6 7 4 7 3 4,340,700 2,003,400 7 72,003,400 2,671,200 5 5 5 1 6 6 6 8 3,672,900 3,339,000 6 61,335,600 1,669,500 2 5 3 5 3 4 3 3 1,836,450 2,838,150 3 31,335,600 2,003,400 2 5 3 4 3 4 3 2 1,836,450 2,504,250 3 32,003,400 1,836,450 3 5 3 1 3 5 3 6 2,003,400 2,838,150 5 53,339,000 3,672,900 5 4 5 5 3 5 2 3,339,000 1,502,550 7 71,335,600 2,671,200 4 2 4 4 4 3 4 5 2,671,200 2,337,300 5 51,335,600 1,669,500 3 3 3 3 2 3 4 2,003,400 1,502,550 4 43,339,000 1,836,450 5 5 5 2 5 5 3 3,339,000 1,669,500 5 57,345,800 8,347,500 14 18 14 17 16 22 16 23 10,017,000 ### 18 18

0 0 0 03,339,000 2,504,250 8 8 8 8 8 8 8 8 5,342,400 5,342,400 10 10

0 0 0 00 0 0 00 0 0 00 0 0 0

OBJECTIVE C3 2010

Nov Dec CATATAN

5 3 3,005,100 10,684,800 4% 7%5 3 3,005,100 11,185,650 3% 6%

45 50 ### 61,270,650 9% 41%5 3 3,005,100 10,183,950 3% 8%8 3 3,505,950 11,185,650 13% 15%8 3 3,505,950 17,529,750 5% 28%5 3 3,005,100 10,684,800 8% 11%

45 50 ### 61,270,650 6% 20%5 5 2,337,300 5,843,250 0% 12%

20 20 ### 32,388,300 0% 58%5 5 3,339,000 13,022,100 0% 47%

85 90 ### ### 10% 39%8 3 3,505,950 16,695,000 31% 63%5 3 2,504,250 9,349,200 5% 14%8 3 4,006,800 12,187,350 2% 5%

90 100 ### ### 0% 54%35 35 ### 48,081,600 0% 15%30 30 ### 36,729,000 0% 46%40 30 ### 50,585,850 16% 26%50 50 ### 73,458,000 0% 46%2 4 1,335,600 3,839,850 0% 6%3 3 2,003,400 7,011,900 13% 15%5 3 3,005,100 10,017,000 19% 10%5 5 3,339,000 11,018,700 0% 23%3 3 2,003,400 6,844,950 13% 14%2 2 1,001,700 2,003,400 0% 3%3 3 2,003,400 6,844,950 5% 6%0 0 0 500,850 0% 0%

30 40 ### 61,771,500 57% 11%0 0 0 1,502,550 0% 1%0 0 0 500,850 0% 0%8 11 7,178,850 20,200,950 25% 41%0 0 0 0 0% 0%

36 35 ### 45,410,400 0% 12%137 120 ### ### 28% 16%

0 0 0 0 0% 0%0 0 0 500,850 0% 0%0 0 0 0 0% 0%0 0 0 0 0% 0%

21 20 ### 26,712,000 4% 7%20 24 ### 26,044,200 4% 18%90 90 ### ### 250% 39%45 45 ### 70,119,000 38% 7%3 3 2,003,400 6,010,200 0% 2%3 3 2,003,400 6,010,200 0% 5%

10 5 5,843,250 18,364,500 30% 18%50 60 ### 79,301,250 14% 66%

VALUE (c3)

TOTAL OBJ 2010

Curr Sales VS Potensi

Objective VS

Potensi

7 5 4,841,550 14,524,650 8% 44%10 5 5,843,250 18,531,450 8% 48%5 3 3,505,950 16,695,000 0% 19%

55 45 ### 79,301,250 83% 99%25 25 ### 39,233,250 63% 67%35 36 ### 44,408,700 21% 61%30 40 ### 45,076,500 7% 50%

0 38,398,500 38% 64%7 7 4,674,600 10,017,000 44% 66%3 3 2,671,200 10,684,800 82% 82%

50 60 ### 80,970,750 0% 38%3 3 2,003,400 6,678,000 13% 35%3 3 2,003,400 7,345,800 31% 52%

30 30 ### 44,241,750 31% 33%30 30 ### 48,415,500 3% 50%15 15 ### 20,034,000 0% 81%60 70 ### ### 8% 36%65 70 ### ### 25% 48%65 70 ### ### 17% 52%65 70 ### 83,475,000 4% 23%30 25 ### 53,257,050 28% 74%60 45 ### 75,127,500 10% 21%60 50 ### 81,805,500 3% 17%1 1 667,800 2,003,400 0% 6%

30 20 ### 48,415,500 13% 15%12 10 7,011,900 15,192,450 6% 9%1 1 667,800 3,005,100 63% 8%1 1 667,800 2,003,400 0% 3%

12 10 7,011,900 15,192,450 5% 9%4 4 2,671,200 7,011,900 63% 32%7 5 3,839,850 12,521,250 7% 12%1 1 667,800 2,003,400 13% 3%5 5 3,339,000 9,683,100 4% 6%

30 30 ### 54,926,550 17% 114%30 30 ### 57,263,850 26% 89%5 5 3,339,000 9,683,100 4% 6%1 1 667,800 2,003,400 0% 3%1 1 667,800 2,170,350 10% 3%7 7 4,674,600 11,018,700 11% 13%6 6 4,006,800 9,683,100 57% 15%3 3 2,003,400 5,175,450 21% 5%3 3 2,003,400 5,175,450 24% 8%5 5 3,339,000 7,345,800 54% 14%7 7 4,674,600 11,352,600 9% 16%5 5 3,339,000 7,345,800 52% 54%4 4 2,671,200 6,010,200 100% 107%5 5 3,339,000 10,017,000 8% 16%

18 18 ### 29,383,200 32% 7%0 0 0% 0%

10 10 6,678,000 15,359,400 33% 11%

0 0 0% 0%0 0 0% 0%0 0 0% 0%0 0 0% 0%

Date post:	28-Jun-2015
Category:	Documents
Upload:	bagayaan
View:	85 times
Download:	6 times

LAYER Kalimantan New

Documents